Literature DB >> 7568227

Delivery of herpesvirus and adenovirus to nude rat intracerebral tumors after osmotic blood-brain barrier disruption.

G Nilaver1, L L Muldoon, R A Kroll, M A Pagel, X O Breakefield, B L Davidson, E A Neuwelt.   

Abstract

The delivery of viral vectors to the brain for treatment of intracerebral tumors is most commonly accomplished by stereotaxic inoculation directly into the tumor. However, the small volume of distribution by inoculation may limit the efficacy of viral therapy of large or disseminated tumors. We have investigated mechanisms to increase vector delivery to intracerebral xenografts of human LX-1 small-cell lung carcinoma tumors in the nude rat. The distribution of Escherichia coli lacZ transgene expression from primary viral infection was assessed after delivery of recombinant virus by intratumor inoculation or intracarotid infusion with or without osmotic disruption of the blood-brain barrier (BBB). These studies used replication-compromised herpes simplex virus type 1 (HSV; vector RH105) and replication-defective adenovirus (AdRSVlacZ), which represent two of the most commonly proposed viral vectors for tumor therapy. Transvascular delivery of both viruses to intracerebral tumor was demonstrated when administered intraarterially (i.a.) after osmotic BBB disruption (n = 9 for adenovirus; n = 7 for HSV), while no virus infection was apparent after i.a. administration without BBB modification (n = 8 for adenovirus; n = 4 for HSV). The thymidine kinase-negative HSV vector infected clumps of tumor cells as a result of its ability to replicate selectively in dividing cells. Osmotic BBB disruption in combination with i.a. administration of viral vectors may offer a method of global delivery to treat disseminated brain tumors.

Entities:  

Mesh:

Year:  1995        PMID: 7568227      PMCID: PMC40896          DOI: 10.1073/pnas.92.21.9829

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  19 in total

1.  Delivery of ultraviolet-inactivated 35S-herpesvirus across an osmotically modified blood-brain barrier.

Authors:  E A Neuwelt; M A Pagel; R D Dix
Journal:  J Neurosurg       Date:  1991-03       Impact factor: 5.115

2.  Ribonucleotide reductase encoded by herpes simplex virus is a determinant of the pathogenicity of the virus in mice and a valid antiviral target.

Authors:  J M Cameron; I McDougall; H S Marsden; V G Preston; D M Ryan; J H Subak-Sharpe
Journal:  J Gen Virol       Date:  1988-10       Impact factor: 3.891

3.  Beta-galactosidase as a marker in the peripheral and neural tissues of the herpes simplex virus-infected mouse.

Authors:  D Y Ho; E S Mocarski
Journal:  Virology       Date:  1988-11       Impact factor: 3.616

4.  Thymidine kinase-negative herpes simplex virus mutants establish latency in mouse trigeminal ganglia but do not reactivate.

Authors:  D M Coen; M Kosz-Vnenchak; J G Jacobson; D A Leib; C L Bogard; P A Schaffer; K L Tyler; D M Knipe
Journal:  Proc Natl Acad Sci U S A       Date:  1989-06       Impact factor: 11.205

5.  Cytotoxicity of a replication-defective mutant of herpes simplex virus type 1.

Authors:  P A Johnson; A Miyanohara; F Levine; T Cahill; T Friedmann
Journal:  J Virol       Date:  1992-05       Impact factor: 5.103

6.  Primary CNS lymphoma treated with osmotic blood-brain barrier disruption: prolonged survival and preservation of cognitive function.

Authors:  E A Neuwelt; D L Goldman; S A Dahlborg; J Crossen; F Ramsey; S Roman-Goldstein; R Braziel; B Dana
Journal:  J Clin Oncol       Date:  1991-09       Impact factor: 44.544

7.  In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors.

Authors:  K W Culver; Z Ram; S Wallbridge; H Ishii; E H Oldfield; R M Blaese
Journal:  Science       Date:  1992-06-12       Impact factor: 47.728

8.  Introduction of a foreign gene (Escherichia coli lacZ) into rat neostriatal neurons using herpes simplex virus mutants: a light and electron microscopic study.

Authors:  Q Huang; J P Vonsattel; P A Schaffer; R L Martuza; X O Breakefield; M DiFiglia
Journal:  Exp Neurol       Date:  1992-03       Impact factor: 5.330

9.  Assessment of ganciclovir toxicity to experimental intracranial gliomas following recombinant adenoviral-mediated transfer of the herpes simplex virus thymidine kinase gene by magnetic resonance imaging and proton magnetic resonance spectroscopy.

Authors:  B D Ross; B Kim; B L Davidson
Journal:  Clin Cancer Res       Date:  1995-06       Impact factor: 12.531

10.  Gene expression from recombinant viral vectors in the central nervous system after blood-brain barrier disruption.

Authors:  S E Doran; X D Ren; A L Betz; M A Pagel; E A Neuwelt; B J Roessler; B L Davidson
Journal:  Neurosurgery       Date:  1995-05       Impact factor: 4.654

View more
  27 in total

Review 1.  HSV-1-based vectors for gene therapy of neurological diseases and brain tumors: part II. Vector systems and applications.

Authors:  A Jacobs; X O Breakefield; C Fraefel
Journal:  Neoplasia       Date:  1999-11       Impact factor: 5.715

Review 2.  Nonneurotropic adenovirus: a vector for gene transfer to the brain and gene therapy of neurological disorders.

Authors:  Pedro R Lowenstein; Donata Suwelack; Jinwei Hu; Xianpeng Yuan; Maximiliano Jimenez-Dalmaroni; Shyam Goverdhana; Maria G Castro
Journal:  Int Rev Neurobiol       Date:  2003       Impact factor: 3.230

Review 3.  Novel delivery strategies for glioblastoma.

Authors:  Jiangbing Zhou; Kofi-Buaku Atsina; Benjamin T Himes; Garth W Strohbehn; W Mark Saltzman
Journal:  Cancer J       Date:  2012 Jan-Feb       Impact factor: 3.360

4.  Quantitative evaluation of monocyte transmigration into the brain following chemical opening of the blood-brain barrier in mice.

Authors:  Jianmei Wu; Shiming Yang; Haiyan Luo; Lingbing Zeng; Lingbing Ye; Yuanan Lu
Journal:  Brain Res       Date:  2006-08-14       Impact factor: 3.252

Review 5.  The status of gene therapy for brain tumors.

Authors:  Giulia Fulci; E Antonio Chiocca
Journal:  Expert Opin Biol Ther       Date:  2007-02       Impact factor: 4.388

6.  Complement depletion facilitates the infection of multiple brain tumors by an intravascular, replication-conditional herpes simplex virus mutant.

Authors:  K Ikeda; H Wakimoto; T Ichikawa; S Jhung; F H Hochberg; D N Louis; E A Chiocca
Journal:  J Virol       Date:  2000-05       Impact factor: 5.103

Review 7.  Gene therapy for the nervous system: challenges and new strategies.

Authors:  Casey A Maguire; Servio H Ramirez; Steven F Merkel; Miguel Sena-Esteves; Xandra O Breakefield
Journal:  Neurotherapeutics       Date:  2014-10       Impact factor: 7.620

8.  The enhancer domain of the human cytomegalovirus major immediate-early promoter determines cell type-specific expression in transgenic mice.

Authors:  J F Baskar; P P Smith; G Nilaver; R A Jupp; S Hoffmann; N J Peffer; D J Tenney; A M Colberg-Poley; P Ghazal; J A Nelson
Journal:  J Virol       Date:  1996-05       Impact factor: 5.103

9.  Rat model of blood-brain barrier disruption to allow targeted neurovascular therapeutics.

Authors:  Jacob A Martin; Alexander S Maris; Moneeb Ehtesham; Robert J Singer
Journal:  J Vis Exp       Date:  2012-11-30       Impact factor: 1.355

Review 10.  Recent progress towards development of effective systemic chemotherapy for the treatment of malignant brain tumors.

Authors:  Hemant Sarin
Journal:  J Transl Med       Date:  2009-09-01       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.